Protagonist Therapeutics, Inc. (PTGX): Price and Financial Metrics

Protagonist Therapeutics, Inc. (PTGX): $16.68

0.45 (-2.63%)

POWR Rating

Component Grades








PTGX Price/Volume Stats

Current price $16.68 52-week high $30.10
Prev. close $17.13 52-week low $7.24
Day low $16.33 Volume 1,388,400
Day high $17.31 Avg. volume 1,213,162
50-day MA $18.77 Dividend yield N/A
200-day MA $19.72 Market Cap 959.60M

PTGX Stock Price Chart Interactive Chart >


  • Sentiment is the dimension where PTGX ranks best; there it ranks ahead of 69.79% of US stocks.
  • PTGX's strongest trending metric is Value; it's been moving down over the last 178 days.
  • PTGX's current lowest rank is in the Stability metric (where it is better than 2.19% of US stocks).

PTGX Stock Summary

  • The ratio of debt to operating expenses for PROTAGONIST THERAPEUTICS INC is higher than it is for about just 6.5% of US stocks.
  • PTGX's price/sales ratio is 1,237.67; that's higher than the P/S ratio of 99.52% of US stocks.
  • As for revenue growth, note that PTGX's revenue has grown -98.17% over the past 12 months; that beats the revenue growth of just 0.81% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to PROTAGONIST THERAPEUTICS INC, a group of peers worth examining would be RLAY, KRTX, RAPT, AUR, and OPT.
  • Visit PTGX's SEC page to see the company's official filings. To visit the company's web site, go to

PTGX Valuation Summary

  • In comparison to the median Healthcare stock, PTGX's price/sales ratio is 27027.66% higher, now standing at 1275.
  • PTGX's price/sales ratio has moved NA NA over the prior 85 months.

Below are key valuation metrics over time for PTGX.

Stock Date P/S P/B P/E EV/EBIT
PTGX 2023-07-26 1275.0 5.1 -7.8 -6.9
PTGX 2023-07-25 1290.3 5.1 -7.9 -7.0
PTGX 2023-07-24 1305.0 5.2 -8.0 -7.1
PTGX 2023-07-21 1332.9 5.3 -8.2 -7.3
PTGX 2023-07-20 1326.3 5.3 -8.1 -7.2
PTGX 2023-07-19 1329.0 5.3 -8.1 -7.3

PTGX Growth Metrics

    Its 4 year net cashflow from operations growth rate is now at -16.03%.
  • Its 3 year cash and equivalents growth rate is now at 40.51%.
  • Its 2 year cash and equivalents growth rate is now at 63.52%.
Over the past 49 months, PTGX's revenue has gone down $4,656,000.

The table below shows PTGX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 35.198 -103.441 -130.106
2022-06-30 45.484 -106.71 -132.678
2022-03-31 46.89 -116.775 -122.483
2021-12-31 27.357 -107.865 -125.551
2021-09-30 24.39 -99.793 -107.53
2021-06-30 27.218 -87.61 -81.489

PTGX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PTGX has a Quality Grade of D, ranking ahead of 12.65% of graded US stocks.
  • PTGX's asset turnover comes in at 0.07 -- ranking 291st of 682 Pharmaceutical Products stocks.
  • RGNX, MBIO, and MTEM are the stocks whose asset turnover ratios are most correlated with PTGX.

The table below shows PTGX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.070 1 -0.571
2021-06-30 0.088 1 -0.513
2021-03-31 0.117 1 -0.538
2020-12-31 0.127 1 -0.678
2020-09-30 0.140 1 -0.800
2020-06-30 0.100 1 -0.977

PTGX Price Target

For more insight on analysts targets of PTGX, see our PTGX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $31.75 Average Broker Recommendation 1.44 (Moderate Buy)

Protagonist Therapeutics, Inc. (PTGX) Company Bio

Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The company was founded in 2006 and is based in Milpitas, California.

PTGX Latest News Stream

Event/Time News Detail
Loading, please wait...

PTGX Latest Social Stream

Loading social stream, please wait...

View Full PTGX Social Stream

Latest PTGX News From Around the Web

Below are the latest news stories about PROTAGONIST THERAPEUTICS INC that investors may wish to consider to help them evaluate PTGX as an investment opportunity.

Protagonist Therapeutics to Present at Upcoming Investor Conferences

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in fireside chat presentations and host one-on-one meetings at the Wells Fargo and H.C.

Yahoo | September 5, 2023

Protagonist Therapeutics (NASDAQ:PTGX) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, Protagonist Therapeutics...

Yahoo | August 24, 2023

Protagonist Therapeutics Reports Granting of Inducement Award

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today reported that on August 15, 2023, it issued inducement awards to Christine Rocha, the Company's recently hired Vice President, Clinical Operations, in accordance with the terms of Ms. Rocha's employment offer letter.

Yahoo | August 16, 2023

Protagonist Receives $34 Million from Warrant Exercises

Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced it has received approximately $34.4 million in proceeds from the exercise of warrants to purchase 2.75 million shares of the Company's Common Stock.

Yahoo | August 9, 2023

Protagonist Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.

Yahoo | August 3, 2023

Read More 'PTGX' Stories Here

PTGX Price Returns

1-mo -15.84%
3-mo -39.61%
6-mo -26.91%
1-year 97.86%
3-year -14.68%
5-year 64.82%
YTD 52.89%
2022 -68.10%
2021 69.64%
2020 185.96%
2019 4.75%
2018 -67.64%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!